Trial reportJournal of psychopharmacology (Oxford, England)2012
Effects of 21 days of varenicline versus placebo on smoking behaviors and urges among non-treatment seeking smokers.
Trial report in Journal of psychopharmacology (Oxford, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00948155 (Assessment of Smoking Topography and Behaviors During Response to Varenicline), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of Smoking Topography and Behaviors During Response to Varenicline
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Pilot Trial of a Behavioral Economics-Informed Clinical Decision Support Alert to Improve Inpatient Tobacco Use Treatment Rates.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Daily Cigarette Abstinence and Smoking Rate With Varenicline: Relationships With Treatment, Craving, and Affect During the First Week of the Quit Attempt.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Sex-Specific Mediation of Pre-Quit Smoking Reduction: Secondary Analysis of a Randomized Controlled Trial Extending Varenicline Preloading.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2025Trial
- Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.Addiction (Abingdon, England) · 2025Trial
- Effect of Extending the Duration of Prequit Treatment With Varenicline on Smoking Abstinence: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder.Drug and alcohol dependence · 2021Trial
- The impact of three weeks of pre-quit varenicline on reinforcing value and craving for cigarettes in a laboratory choice procedure.Psychopharmacology · 2021Trial
- The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Trial
- Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms.Addiction (Abingdon, England) · 2017Trial
- Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder.Psychiatry research. Neuroimaging · 2017Trial
- Does Extended Pre Quit Bupropion Aid in Extinguishing Smoking Behavior?Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2015Trial
- Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers.Pharmacology, biochemistry, and behavior · 2015Trial
- Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial.JAMA · 2015Trial
- Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.The American journal of drug and alcohol abuse · 2015Trial
- Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings.Psychopharmacology · 2014Trial
- The impact of pre-cessation varenicline on behavioral economic indices of smoking reinforcement.Addictive behaviors · 2014Trial
- Determinants of successful smoking cessation in outpatient settings: A comparative analysis of varenicline and free program interventions.Tobacco induced diseases · 2025Article
- Extending varenicline preloading to 6 weeks facilitates smoking cessation: A single-site, randomised controlled trial.EClinicalMedicine · 2020Article
- Nomogram to predict successful smoking cessation in a Chinese outpatient population.Tobacco induced diseases · 2020Article
- Facilitated Extinction Training to Improve Pharmacotherapy for Smoking Cessation: A Pilot Feasibility Trial.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Varenicline promotes smoking cessation and reduces urges to smoke. However, the mechanisms associated with these effects and their time course are not well characterized. One mechanism may be extinction, but the duration of the current dosing protocol may not be sufficient. We examined the effect of extended pre-treatment with varenicline on smoking behavior among 17 non-treatment seeking adult smokers. Using a within-subjects, double-blind, placebo-controlled crossover design, participants received standard dosing of varenicline for 21 days, followed by a 14-day washout period and 21 days of placebo; order counterbalanced. Cigarettes per day (CPD), smoking topography, smoking urges (QSU), and side effects were assessed every three days. Biomarkers (e.g. nicotine metabolites) were collected on days 1, 7, and 21. There was a significant drug by time interaction indicating a reduction in CPD during varenicline phase (between days 10-21), but no reduction during placebo. Varenicline also led to reductions in nicotine metabolites and urges to smoke. Among this sample of non-treatment seeking smokers, varenicline significantly reduced smoking behavior. Results have important treatment implications because changes in CPD and craving did not occur until after the typical one-week run-up period. This suggests that a longer duration of pre-treatment may be beneficial for some smokers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.